* Axcella Health Inc AXLA.OQ AXLA.O is expected to show
no
change in quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Axcella Health Inc
is for
a loss of $1.25 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Axcella
Health
Inc is GBp15,558.91, above its last closing price of $6.62.
This summary was machine generated October 27 at 18:33 GMT. All
figures in US dollars unless otherwise stated